Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on March 27, 2026 - Key Managerial Personnels who are authorized to determine materiality of an event or information and make necessary disclosures to the Stock Exchange(s) pursuant to Regulation 30 of SEBI Listing Regulations

Biocon's board, meeting on March 27, 2026, approved a major leadership overhaul effective April 1, 2026, as part of the previously announced integration of Biocon Biologics into a unified global biopharma entity. CEO & MD Siddharth Mittal and Interim CFO Mukesh Kamath will step down on March 31, 2026 to take up other roles within the Biocon Group. Shreehas Pradeep Tambe, currently CEO & MD of Biocon Biologics (BBL), will become Biocon's CEO & MD for a 5-year term (subject to shareholder approval), and BBL's CFO Kedar Narayan Upadhye will take over as Biocon's CFO. Akhilesh Nand (BBL's Company Secretary) joins as Head of Governance, Risk & Compliance, while Naveen Narayanan and Mandar Ghatnekar from BBL move into CHRO and CTO roles respectively. Additionally, 7 senior management personnel (including CCO, CSO, COO, HR Head, Quality, Supply Chain, and API Commercials heads) will cease in their roles on March 31, 2026. The board also approved a list of 5 KMPs authorized to determine materiality of events for stock exchange disclosures.